title: Effects of isradipine on platelet function in hypertension at rest and during exercise.
abstract: The effects of eight weeks of treatment with isradipine (1.25 mg twice daily for four weeks, followed by 2.5 mg twice daily for four weeks) on ex vivo platelet function were investigated in ten male patients with hypertension. Systolic and diastolic blood pressures, platelet aggregation in response to adenosine diphosphate (ADP), serum thromboxane B2, and beta-thromboglobulin levels were significantly decreased (P less than .05) at rest before exercise ergometry, during exercise, and at rest after exercise. The platelet count and plasma levels of 6-oxo-prostaglandin F1 alpha (PGF1 alpha) were not affected by isradipine. It is concluded that treatment of hypertension with a compound that lowers blood pressure and inhibits platelet activation may be of clinical benefit when routinely applied in hypertensive patients.
authors.affiliation: Department of Internal Medicine II, Policlinic, Vienna, Austria.
authors.forename: P
authors.initials: P
authors.lastname: Fitscha
authors.forename: I
authors.initials: I
authors.lastname: Virgolini
authors.forename: F
authors.initials: F
authors.lastname: Rauscha
authors.forename: H
authors.initials: H
authors.lastname: Sinzinger
mesh_terms: D015121:6-Ketoprostaglandin F1 alpha / Q000097:blood; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000959:Antihypertensive Agents / Q000494:pharmacology* / Q000627:therapeutic use; D001792:Blood Platelets / Q000187:drug effects* / Q000502:physiology; D001794:Blood Pressure / Q000187:drug effects; D015444:Exercise; D005080:Exercise Test; D006801:Humans; D006973:Hypertension / Q000097:blood* / Q000188:drug therapy; D017275:Isradipine; D008297:Male; D008875:Middle Aged; D010974:Platelet Aggregation / Q000187:drug effects; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D010976:Platelet Count / Q000187:drug effects; D011725:Pyridines / Q000494:pharmacology* / Q000627:therapeutic use; D012146:Rest; D013929:Thromboxane B2 / Q000097:blood; D013997:Time Factors; D001620:beta-Thromboglobulin / Q000032:analysis
chemical_list: D000959:Antihypertensive Agents; D010975:Platelet Aggregation Inhibitors; D011725:Pyridines; D001620:beta-Thromboglobulin; D013929:Thromboxane B2; D015121:6-Ketoprostaglandin F1 alpha; D000244:Adenosine Diphosphate; D017275:Isradipine